Art

J-GLOBAL ID：201802229457751301   Reference number：18A1334087

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)

転移性乳癌に対する隔週のエリブリン療法:多施設第II相前向き研究(JUST-STUDY)

Author (17)： OHTANI Shoichiro (Hiroshima City Hiroshima Citizens Hospital, Hiroshima, JPN) ,  NAKAYAMA Takahiro (Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, JPN) ,  YOSHINAMI Tetsuhiro (Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, JPN) ,  WATANABE Ken-ichi (Hokkaido Cancer Center, Hokkaido, JPN) ,  HARA Fumikata (Shikoku Cancer Center, Ehime, JPN) ,  SAGARA Yasuaki (Hakuaikai Medical Corp. Sagara Hospital, Kagoshima-shi, JPN) ,  KAWAGUCHI Hidetoshi (Matsuyama Red Cross Hospital, Ehime, JPN) ,  HIGAKI Kenji (Higaki Breast Clinic, Hiroshima, JPN) ,  MATSUNAMI Nobuki (Osaka Rosai Hospital, Osaka, JPN) ,  HASEGAWA Yoshie (Hirosaki Municipal Hospital, Aomori, JPN) ,  TAKAHASHI Masato (Hokkaido Cancer Center, Hokkaido, JPN) ,  MIZUTANI Makiko (Osaka National Hospital, Osaka, JPN) ,  MORIMOTO Takashi (Yao Municipal Hospital, Osaka, JPN) ,  SATO Masako (Hokkaido Cancer Center, Hokkaido, JPN) ,  ITOH Mitsuya (Hiroshima City Hiroshima Citizens Hospital, Hiroshima, JPN) ,  MORITA Satoshi (Kyoto Univ. Graduate School of Medicine, Kyoto, JPN) ,  MASUDA Norikazu (Osaka National Hospital, Osaka, JPN)
Material： Breast Cancer
Volume： 25  Issue： 4  Page： 438-446  Publication year： Jul. 2018 
JST Material Number： L3971A  ISSN： 1340-6868  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： *breast tumor ,...
Semi thesaurus term： *Breast cancer metastatic

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1334087&from=J-GLOBAL&jstjournalNo=L3971A") }}

JST classification (1)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (1)： Eribulin

Reference (25)：

• Cortes J, Vidal M. Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat. 2012;133:821-30.
• Jain S, Cigler T. Eribulin mesylate in the treatment of metastatic breast cancer. Biologics. 2012;6:21-9.
• Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin-a review of preclinical and clinical studies. Crit Rev Oncol Hematol. 2012;81:163-84.
• Inoue K, Saito T, Okubo K, Kimizuka K, Yamada H, Sakurai T, et al. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance. Breast Cancer Res Treat. 2016;157:295-305.
• US Food and Drug Administration. Highlights of prescribing information: Halaven. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf. Accessed 01 Mar 2017.

Terms in the title (6)： 転移性乳癌 ,  エリブリン ,  療法 ,  施設 ,  第II相 ,  研究